FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
Publishing timestamp: 2024-03-14 19:08:37
Summary
The FDA approved Rezdiffra as the first-ever treatment for the common and potentially deadly liver disease NASH. Madrigal Pharmaceuticals succeeded where larger companies have failed, leading to a significant jump in their shares. The drug will be available in April and is specifically approved to treat patients with NASH who also have moderate-to-advanced liver scarring. The medication works by activating the thyroid hormone receptor in the liver to reduce fat accumulation.
Sentiment: POSITIVE
Tickers: MDGL, NOVO.B-DK, NVO, LLY,
Keywords: eli lilly and co, biotechnology, business news, biotech and pharmaceuticals, pharmaceuticals, breaking news: business, health care industry, novo nordisk a/s, business, madrigal pharmaceuticals inc,